CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy(St. Jude Children'S Research Hospital)

N/A

Report date: 2025/01/17 20:00:43

Base Information

Drug NameCD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy(St. Jude Children'S Research Hospital)
Drug Alias Name1922CAR Therapy(St. Jude Children'S Research Hospital)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsCD22 modulators
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSt. Jude Children'S Research Hospital
China Registration ClassN/A

Develop Information

Active CompaniesSt. Jude Children'S Research Hospital
Inactive CompaniesN/A
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A